The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
 
Jacob M. Sands
Consulting or Advisory Role - AstraZeneca; Celgene; Foundation Medicine; Incyte; Medtronic; Merck; Trovagene
 
Toshio Shimizu
Honoraria - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - 3D Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Five Prime Therapeutics; PharmaMar; Takeda/Millennium
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
 
Jonathan Greenberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Exelixis (Inst); Incyte (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Roche (Inst)
 
Fumiaki Kobayashi
Employment - Daiichi Sankyo
 
Yutaka Noguchi
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Daisuke Okajima
Employment - Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo
 
Alexander I. Spira
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomonari Yamashita
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Aaron Elliott Lisberg
Employment - Boston Scientific
Stock and Other Ownership Interests - Boston Scientific
Consulting or Advisory Role - AstraZeneca